SIGA Technologies (SIGA) is back in focus after its 2025 earnings release, which showed lower annual revenue and net income, alongside ongoing contracts for TPOXX, pediatric development funding, and ...
SIGA Technologies (NasdaqGM:SIGA) has secured new multi-year international contracts for its antiviral TPOXX. The company recently received a $13 million procurement order from a country in the Asia ...
SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that management ...
Generated TPOXX Product Revenues of $88 Million in 2025 Received $13 Million International Procurement Order for Oral TPOXX in January 2026 ...
SIGA Technologies, Inc. recently reported its fourth quarter and full-year 2025 results, with full-year revenue of US$94.57 million and net income of US$23.28 million, but a sharp year-on-year drop in ...
Several healthcare stocks associated with mpox are seeing increased attention Thursday after the World Health Organization declared a public health emergency in response to an mpox outbreak in Africa.
On Thursday, the Japan Ministry of Health, Labour and Welfare approved SIGA Technologies (NASDAQ:SIGA) antiviral treatment TEPOXX (tecovirimat 200 mg capsules) for smallpox, mpox, cowpox, as well as ...
It’s déjà vu for Siga Technologies and its smallpox antiviral Tpoxx. At an interim analysis of a second mpox trial, the drug again missed the mark on a key measure of disease resolution. In patients ...
Siga Technologies ( (SIGA)) has released its Q3 earnings. Here is a breakdown of the information Siga Technologies presented to its investors. SIGA Technologies, Inc. is a commercial-stage ...
SIGA Technologies, Inc. has announced the appointment of Retired U.S. Army General John "Jack" Keane to its Board of Directors, effective immediately. General Keane, a four-star general with 37 years ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results